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Abstract 
 
Single-donor dominance is observed in the majority of patients following double cord blood 
transplantation (dCBT), however the biological basis for this outcome is poorly understood. To 
investigate the possible influence of specific cell lineages on dominance, flow cytometric 
assessment for CD34+, CD14+, CD20+, CD3-CD56+, CD3+CD56+ (NKT), and T-cell subsets 
(CD4+, CD8+, Memory, Naïve, and Regulatory) was performed on individual units.  Subsets 
were calculated as infused viable cells/kg of recipient actual weight, with sixty patients included 
in the final analysis. Higher CD3+/kg dose was statistically concordant with the dominant unit in 
72% of cases (p=0.0006). Further T-cell subset analyses showed dominance was correlated 
more with the naive CD8+ cell subset (71% concordance; p=0.009) than the naive CD4+ cell 
subset (61% concordance; p=0.19). These data indicate that a greater total CD3+/kg cell dose 
and in particular naïve CD3+CD8+ T-cells, may play an important role in determining single 
donor dominance after dCBT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Page 3 
Introduction 
Cord blood transplantation (CBT) is an accepted treatment for adults and children 
with hematologic malignancies [1, 2]. In order to overcome the limitation in cell dose 
provided by a single CB graft and to more reliably achieve sustained donor engraftment, 
double unit CBT (dCBT) is commonly performed for adult and larger adolescent patients 
[3, 4]. Interestingly, in the vast majority of dCBT recipients, only one unit emerges as the 
source of long-term hematopoiesis [1,2,5]. However, the factors that determine which of 
the two units will achieve single donor dominance after dCBT remain poorly understood.  
Unit parameters such as total nucleated cell (TNC) and CD34+ cell doses, viability, 
degree of HLA-matching and order of infusion have not been uniformly associated with 
donor dominance [6-8]. Conversely, CD3+ cell dose is emerging as a reliable predictor 
of single donor dominance [9-11]. Indeed, in a report from our institution the first direct 
evidence that only effector T-cells derived from the dominant unit produced interferon-γ 
in response to cells derived from the non-engrafting unit [12] was shown. More recently, 
we also provided strong evidence that the unit with higher CD3 chimerism at day 7 is 
the one more likely to be the dominant unit [13].  
Herein, the association of infused CD3 cell dose, and in addition possible 
correlations of specific T cell subsets (CD3+/CD8+, CD3+/CD4+, naïve/memory, and 
regulatory) with the emergence of single unit donor dominance were further 
investigated. An extended immunophenotyping flow cytometry panel was performed on 
a sample obtained from each CB unit just prior to infusion in 72 consecutive patients 
undergoing dCBT for hematologic malignancies. Infused cell doses were calculated and 
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used to investigate whether any specific T-cell subsets were also highly correlated with 
single donor dominance.  
 
Methods 
Patient/Donor Characteristics  
Between January 2008 and May 2011 72 patients received a dCBT at our 
institution. Twelve patients (17%) were excluded because they either died before 
obtaining informative chimerism data or had primary/secondary graft failure. As per 
institutional priority, patients received a CBT if they lacked an available HLA-compatible 
related or matched unrelated donor. All patients received unrelated donor CB grafts, 
which were 4/6- to 6/6-matched at HLA-A, B, and DRB1 antigens.  HLA-typing was 
performed at the antigen level for HLA-A and B, and high resolution HLA-typing was 
performed for HLA-DRB1 alleles.  The individual CB units were at least 3/6-HLA-A, B, 
and DRB1 matched to each other, and each contained a minimum of 1.5 x 107 TNC/kg.  
All study activities were approved by the FHCRC Institutional Review Board, and all 
participants provided written informed consent according to the principles of the 
Declaration of Helsinki. 
 
Conditioning regimens and GVHD prophylaxis 
Myeloablative conditioning consisted of cyclophosphamide (Cy) 60 mg/kg 
intravenously daily for 2 days, total body irradiation (TBI) 1320 or 1200 cGy, and 
fludarabine (Flu) 40 mg/m2 intravenously daily for 3 days. Eleven patients received Flu 
at a dose of 30 mg/m2 intravenously daily for 5 days, Treosulfan (Treo) at 14 gm/m2  
intravenously daily for 3 days, and a single fraction of TBI 200 cGy. Reduced intensity 
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conditioning consisted of Flu 40 mg/m2 intravenously daily for 5 days, a single dose of 
Cy 50 mg/kg intravenously, and a single fraction of TBI 200 or 300 cGy.  
GVDH prophylaxis consisted of cyclosporine-A along with mycophenolate mofetil 
and emergence of GVHD was treated per treating physician discretion.  
 
Cell dose analysis  
All CB units were thawed and washed by centrifugation prior to resuspension in 
preparation for infusion. Units were infused sequentially with an interval of less than 45 
minutes between each infusion. A small aliquot was removed for analysis from the final 
product just prior to infusion. This sample was then processed for measurement of total 
nucleated cells (TNC) and flow cytometric assessment of graft composition. In particular 
the following viable (7-AAD negative) cell subsets were measured by multicolor FACS 
analyses and then expressed as infused cell subset/kg of actual recipient weight: 
stem/progenitors (CD34+), monocytes (CD14+), B (CD20+), NK (CD3-CD56+), NK/T 
(CD3+CD56+), and T-cell subsets (CD3+CD4+, CD3+CD8+, CD45RA-/CD45RO+  
(Memory) CD45RA+/CD45RO- (Naïve), and CD4+CD25+CD127lo for Regulatory T-cells).   
Results were used to calculate total cell subset/kg of recipient weight for each cord 
blood unit. 
 
Chimerism analysis 
Analysis of host and cord blood unit chimerism was performed on flow cytometry 
sorted CD3+, CD56+, and CD33+ fractions of peripheral blood on days 7, 14, 21, 28, 
56, and 80 after transplantation. Whole bone marrow chimerism was performed on days 
28, 56 and 80 after transplantation. DNA chimerism analysis was performed by 
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amplified fragment length polymorphism (detection sensitivity 1-5%, range of accuracy 
±5%) [14]. Single donor dominance was generally defined as more than 95% single unit 
derived cells in all fractions. In the rare case of the two CB units engrafting long-term, 
the unit contributing to >60% hematopoiesis was considered the dominant one. 
Similarly, in patients who died before day 100, the dominant unit was considered the 
one contributing to >60% hematopoiesis at the time of the last chimerism result.  
 
Statistical analysis 
If the infused dose of a cell subset was not associated with subsequent 
development of single-donor dominance, the expected concordance between the 
dominant unit and a higher or lower dose of that subset should be the random chance of 
50% (e.g. a coin flip). Thus, a one-sample test of the null hypothesis that a binomial 
proportion is equal to 0.5 was used to test the pair-wise association of concordance of 
the relatively higher cell subset dose with unit dominance.  Similarly, in a separate 
analysis, if there was no association between cell dose and unit dominance, the 
expected mean difference in dose between winning and losing units should be zero.  
Accordingly, a one-sample t-test was used to test the null hypothesis that the mean 
difference in cell dose between winning and losing units was zero. Wilcoxon rank sum 
test was used to compare graft characteristics between dominant and non-dominant 
units.    
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Results 
Patient and graft characteristics 
Sixty patients were included in the final analysis. Patient, transplantation and 
graft characteristics are summarized in Table 1. Forty-six (77%) and 14 (23%) received 
a myeloablative (MC) or non-myeloablative conditioning (NMC), respectively. Median 
time to neutrophil engraftment was 13 (Interquartile range [IQR] 7-18) and 25 (IQR 19-
31) after NMC and MC conditioning, respectively. At day +28 post-transplant a dominant 
unit (as defined ≥ 60% chimerism) was observed in all recipients of MC. In particular, in 
all but one patient complete contribution from a single unit (as defined ≥ 95% 
chimerism) was seen at a median time of 14 days (IQR, 14 -21 days). The only patient 
with persistent contribution from both units, still present at 1 year post-transplant, 
received a Treosulfan based conditioning regimen and 2 HLA 6/6 units. In contrast, 
NMC patients initially had mixed donor-host chimerism and at day +28, single donor 
dominance (as defined ≥ 60% chimerism) was observed in only 4 patients. The 
remaining 10 patients converted to single donor dominance at a median time of 56 days 
(IQR 56-80 days) post-transplant, however at day +80 3 patients still had significant 
contribution from both units.  
Among the 120 CB units given to these 60 patients, the degree of matching were 
as follows: HLA-A, -B, -DRB1 matched (n=15); mismatched at 1 Ag (n=44), mismatched 
at 2 Ag (n=61). HLA mismatch was not a critical factor in affecting dominance. Indeed, 
in 6 (10%) cases the unit with the better HLA matching to the recipient became the 
dominant unit while in 9 (15%) cases the unit with less HLA matching predominated. In 
the remaining cases both units had the same degree of HLA mismatching.  
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Influence of CD3+ cells on determining dominant unit 
No significant differences were seen in the median pre-thaw and post-wash TNC 
and CD34+ cell doses and viability post-wash between dominant and non-dominant 
units (Table 2). For some patients, a sample was not pulled or insufficient material was 
available from each double cord blood unit for complete cell subset analysis on both CB 
units (Table 3). Of the 60 cohort patients, 58 had a sufficient sample to determine CD3+, 
CD4+and CD8+ cell doses. In 42 (72%, p=0.0006), 41 (71%, p=0.002) and 45 (78%, 
p<0.0001) cases the unit containing the higher CD3+, CD4+ or CD8+ cell dose became 
the dominant engrafting unit, respectively. In the subset of 14 patients who received 
NMC, the proportion of positive correlation was identical to the whole cohort [CD3 10/14 
(71%); CD8 11/14 (78%) and CD4 10/14 (71%)]. In a smaller cohort of 38 patients (28 
MC and 10 NMC) further analysis of various CD4+ and CD8+ subsets showed that only 
the naïve CD8+ cell dose was highly associated with donor dominance (71%, p=0.009) 
while memory CD8+, memory CD4+ and naïve CD4+ cell doses did not significantly 
correlate with the dominant unit (Table 3). This association of a higher ratio of infused 
cell dose with dominance was defined as positive concordance, and is shown 
graphically in Figure 1. As expected in CB products, the total CD8+ cell doses were 
strongly correlated with the majority naïve CD8+ fraction (R=0.90, Figure 2), supporting 
the concept that total viable CD8+ cell dose can be used as surrogate marker for naïve 
CD8 cells infused.  
As an alternative approach to assess cell subset associations with single unit 
dominance, the mean difference in infused cell dose between dominant and non-
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dominant units was also analyzed. This calculation also showed a statistically significant 
difference for CD3+, CD8+, CD4+, naïve CD8+ and naïve CD4+ (Table 4).  
 
Association of other cell subsets 
Among the other cell types analyzed, only higher NKT (68%, p=0.02) and CD20+ 
(68%, p=0.02) were also statistically significantly correlated with donor dominance 
(Table 3). However, the mean difference between dominant and not-dominant unit was 
only statistically significant for NKT but not for CD20+ cells (Table 4).  Viability post-
wash was suggestively concordant (62%, p=0.07) while no statistically significant 
associations with the infused dose of monocytes, NK, or regulatory T-cells were 
observed (Table 3 and 4).  
We also found no significant associations between pre-freeze or post-wash 
infused dose of total cells or CD34+ cells and the likelihood of being the dominant unit. 
Furthermore we did not find any association between the order of infusion and the 
probability of becoming the long-term engrafting unit (p=0.60; Table 3). 
 
Discussion  
The absolute number of T cells infused with CB stem cell grafts is relatively lower 
compared with bone marrow or PBSC products. Nevertheless, in this study evidence is 
provided that having a higher CD8+ cell content, in particular the naïve CD3+CD8+ T-cell 
subset, is an important predictor in determining which CB unit will ultimately 
predominate. Similar to other published reports [9,10], a high concordance was 
observed between greater CD3+/kg content and establishment of single-donor 
dominance. However, to our knowledge, this is the first published report that infused 
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CD3+CD8+ and CD3+CD4+ subsets in the CB graft are significantly correlated with 
emergence of single-donor dominance.  
Furthermore, in this study, it is the naïve CD8+/kg cell dose in particular that is 
most highly statistically associated with unit dominance. Thus, it may be hypothesized 
that naïve CD8+ T-cells in one CB unit, when that unit becomes exposed in vivo to the 
allogeneic antigens expressed by the second CB unit, will become activated.  Having a 
relatively higher content of those naïve CD8+ T-cells will give that unit an advantage in 
facilitating the ultimate rejection of the second CB unit. This hypothesis is supported by 
data from animal models and in vitro testing showing that predominantly naïve T-cells 
can mount an anti-allogeneic response and cause GVHD [15], while transplantation of 
memory CD8+ and CD4+ cells does not result in GVHD reactivity [16,17].  Similarly, our 
results suggest that higher doses of memory CD4+ and CD8+ subsets do not appear to 
influence emergence of single-unit dominance. Although it was not always possible to 
determine the CD8+ subtypes content for each unit, the high correlation between total 
CD8+ and naïve CD8+ in cord blood products allow us to infer that it was also the higher 
infused dose of the naïve population in those cases which was responsible for 
determining the dominant unit.  
The limited number of paired samples available for the naïve T-cell subset 
analyses did not indicate a significant statistical correlation between higher naïve CD4+ 
cell dose and probability of becoming the dominant unit. However when we analyzed 
the results using instead the mean of differences, we did also find a statistically 
significant higher content of naïve CD4+ in the dominant units. It has been shown that 
HLA-alloreactivity is derived from both naïve CD4+ and CD8+ subsets [18], thus this 
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difference in mean infused naïve CD4+ cell dose suggests a potential role for the naïve 
CD4+ along with naïve CD8+ in influencing single unit dominance. 
In support of additional immune-mediated mechanisms determining single unit 
dominance, we also found, a higher infused content of NKT and B-cells in the ultimately 
dominant CB.  NKT cells can exhibit potent direct killing activity, both through MHC-
unrestricted and TCR-mediated mechanisms, against different cell line targets [19]. 
Thus, it is possible that higher NKT content might also influence the emergence of 
single-donor dominance specifically through HLA-mismatched immune-mediated 
rejection responses towards the other CB unit. Similarly, higher numbers of CD20+ cells 
in allogeneic grafts have been previously associated with immune reactions such as 
increased development of chronic GVHD and better clinical outcome [20]. These 
preliminary findings need to be confirmed in future studies and a clinical analysis is 
ongoing at our institution to better clarify the potential role played by NKT and CD20+ 
cells in dCBT. 
In contrast to other published reports, no statistically significant associations 
were found with the infused dose of total cells or CD34+ cells and the dominant CB unit. 
While viable CD34+ dose has been reported as the most important factor in determining 
the unit that will dominate [8], this was not observed in our study. The lack of correlation 
reported here as compared to the study conducted by Scaravandou and colleagues 
may result from differences in the flow cytometric methods used to assess CD34+ cell 
viability after post thaw/wash processing of the cord blood units.  
The results presented in this study strengthen the evidence that the basis for 
single unit predominance is an immunological-mediated rejection mechanism between 
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the two cord blood units. However, besides infused cell dose there are likely to be other 
factors that may play a role such as specific HLA-matching interactions between the 
residual host immune system and the two cord blood donor, interactions between the 
two CB units, the host bone marrow environment, differences in homing efficiencies [21] 
which could also impact which unit will ultimately predominate. Larger studies that 
support multivariate analyses of host and graft characteristics on influencing the 
emergence of a dominant unit after dCBT could improve unit selection criteria. To date, 
unit selection is based on HLA-matching, followed by TNC and/or CD34+ prefreeze 
measurements. Our results, along with findings from other groups [9, 10], support the 
concept that prefreeze CD3 and/or CD8 measurements might further improve these unit 
selection algorithms. Knowing the dose of CD8+ might be even more critical for clinical 
trials that involve graft manipulation. For example, in studies of CD34+ ex-vivo 
expansion [22] focused on just reducing the time to neutrophil engraftment, the unit with 
less CD8+ cells could be chosen for processing since it would have a lower chance of 
long-term predominance. 
In conclusion, in this study we have provided evidence that higher T-cell content, 
in particular the naïve CD3+CD8+ T-cell subset, is an important predictor of which CB 
unit will ultimately predominate. The data support immune-mediated mechanisms as the 
primary driver of single unit dominance.  Having an ability to accurately predict, prior to 
infusion, which CB unit will ultimately become the dominant long-term engrafting unit 
may have practical implications for optimal unit selection. Furthermore, an improved 
understanding of the determinants of short-term and long-term engraftment after dCBT 
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also has implications for ex-vivo graft manipulations, immune reconstitution, and 
disease control. 
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Table 1. Characteristics of the 60 patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Characteristics  
Patient Age, Median Years (IQR) 38.3 (18.6 – 51.4) 
Gender, No (%) 
  Female 
 
30 (50)
Median Recipient Weight in Kg (IQR) 72.0 (59.9-79.8) 
Recipient CMV Serostatus, No (%)
  Positive 
  Negative 
 
36 (60) 
24 (40) 
Transplant Type, No (%) 
  Myeloablative 
  Non-myeloablative 
 
46  (77) 
14  (23)
GVHD Prophylaxis, No (%)  
  Cyclosporine/Mycophenolate 
  
60 (100) 
Disease, No (%) 
   ALL 
   AML 
   MDS 
   CLL 
   Other 
 
18 (30) 
26 (44) 
5 (8) 
4 (7) 
7 (11)
Sex Match, No (%) 
    Match, match 
    Match, mismatch 
    Mismatch, mismatch 
 
22 (37) 
28 (47) 
10 (16)
HLA disparity, No (%) § 
  4/6 + 4/6 
  4/6 + 5/6 
4/6 + 6/6 
5/6 + 5/6 
5/6 + 5/6 
6/6 + 6/6 
 
26 (43) 
9 (15) 
- 
13 (22) 
8 (14) 
4 (6) 
Time to engraftment ** days, (IQR range)
  Myeloablative 
  Non-myeloablative 
 
25 (19-31) 
13  (7-18)
Abbreviations: IQR = Interquartile range; ALL = acute lymphoblastic leukemia; AML = acute 
myeloid leukemia; MDS = myelodysplastic/myeloproliferative diseases; CLL = chronic 
lymphocytic leukemia;    CMV = cytomegalovirus; TNC = total nucleated cell. 
§  HLA matching reflects the lowest HLA-match of the 2 units 
**  The day of neutrophil engraftment was defined as the first of 3 consecutive days of an 
absolute neutrophil count of 500/µl or greater. 
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Table 2. Characteristics of the dominant and non-dominant CB units. 
 
Table 3.  Cell subset/total number of patients where larger infused value was in concordance 
with winning unit / total number of patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factors Dominant Unit 
(n=60)
Non-dominant 
(n=60) 
p-value
TNC x 107/Kg †, Median (IQR) 2.4 (1.9 – 3.3) 2.4 (1.9 – 3.0) 0.18
TNC x 107/Kg  §, Median (IQR) 2.0 (1.6 – 2.6) 1.9 (1.5 – 2.4) 0.15
CD34+ x 106/Kg †, Median (IQR) 0.11 (0.07 – 0.15) 0.10 (0.06 – 0.15) 0.44
CD34+ x 106/Kg §, Median (IQR) 0.12 (0.08 – 0.19) 0.11 (0.07 – 0.19) 0.32
Viability, Median % (IQR) 74.3 (66.5 – 81) 67.6 (63.2 – 77) 0.07
Abbreviations : TNC: Total Nucleated cells; IQR : Interquartile range 
†  Pre-thaw values  
§  Post-wash values 
 
Cell Fractions  
(n = # of evaluable unit pairs) 
Units with positive 
concordance 
n (%,CI 95%) 
P-value 
Total CD8 (58) 45 (78%, 67-88) <0.0001 
Total CD3 (58) 42 (72%, 61-84) 0.0006 
Naïve CD8 (38) 27 (71%, 57-85)  0.009 
Total CD4 (58) 41 (71%, 59-82) 0.002 
CD20 (41) 28 (68% 54-83) 0.02 
NKT (38) 26 (68%, 54-83) 0.02 
Viability post-wash (60) 37 (62%, 49-74) 0.07 
TNC post-wash (60) 35 (59%, 46-71) 0.15 
Naïve CD4 (38) 23 (61%, 45-76) 0.19 
Memory CD4 (38) 23 (61%, 45-76) 0.19 
CD34+ post-wash (60) 34 (57%, 44-69) 0.30 
CD14 (57) 26 (46%, 33-59) 0.51 
NK (39) 18 (46%, 31-62) 0.63 
Order of infusion* 31 (53%, 41-66) 0.60 
CD34 pre-freeze (58) 31 (53%, 41-66) 0.60 
TNC pre-freeze (58) 32 (53%, 36-70) 0.73 
T-reg (34) 18 (53%, 36-70) 0.73 
Memory CD8 (38) 19 (50% 34-66) 1.00 
* Unit infused as first  
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Table 4. Mean of the difference in infused viable cell dose between dominant and non-dominant 
units for each cell subset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell Fractions dose/Kg  Mean difference dominant and 
non-dominant unit (CI 95%) 
P-value 
Total CD8 x 105/Kg 5.96 (3.40 – 8.52) <0.0001 
Naïve CD8 x 105/Kg 4.16 (1.35 – 6.97) 0.006 
Total CD3 x 106/Kg 1.44 (0.55 – 2.32) 0.002 
Total CD4 x 106/Kg 1.05 (0.41 – 1.70) 0.002 
NKT x 104/Kg 1.23 (0.28 – 2.17) 0.02 
Naïve CD4 x 105/Kg 7.22 (0.54 -13.91) 0.04 
Viability post-wash % 3.72 (0.17 – 7.28) 0.04 
CD20 x 105/Kg 2.15 (-0.88 – 5.18) 0.17 
T-reg x 104/Kg -2.06 (-4.89 – 0.78) 0.16 
TNC pre-freeze x 109/Kg 0.11 (-0.09 – 0.32) 0.26 
CD34 post-wash x 106/Kg 1.16 (-1.18 – 3.51) 0.32 
Memory CD8 x 104/Kg 2.04 (-3.45 – 7.52) 0.47 
TNC post-wash x 109/Kg 0.001 (-0.002 – 0.004) 0.39 
CD34 pre-freeze x 106/Kg 0.01 (-0.02 – 0.05) 0.45 
NK x 105/Kg 0.97 (-2.71 – 4.65) 0.61 
Memory CD4 x 104/Kg 4.31 (-8.95-17.56) 0.53 
CD14 x 104/Kg - 2.17 (-30.82 – 26.48) 0.88 
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Figure 1. Ratio between dominant and non-dominant units. A) Total CD8+   B) naïve CD8+. 
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Figure 2. Correlation between total CD8+ and naïve CD8+ cell dose in the units with evaluable 
samples (n=38) (R=0.90). 
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